Notably, the clinical efficacy of IL-1 inhibition (anakinra) and IL-6 inhibition (tocilizumab or sarilumab) was studied in COVID-19 patients with respiratory insufficiency and hyperinflammation. This evidence concerns the gene IL1B and COVID-19.